79O Stock Overview
A specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NuGen Medical Devices Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.056 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.051 |
| Beta | 2.66 |
| 11 Month Change | -16.12% |
| 3 Month Change | -1.40% |
| 1 Year Change | -29.75% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 79O | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.2% | 3.8% | 1.3% |
| 1Y | -29.8% | -6.6% | 7.9% |
Return vs Industry: 79O underperformed the German Medical Equipment industry which returned -5.7% over the past year.
Return vs Market: 79O underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 79O volatility | |
|---|---|
| 79O Average Weekly Movement | 23.2% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 79O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 79O's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Ian Heynen | www.nugenmd.com |
NuGen Medical Devices Inc., a specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, semaglutide, and growth and fertility hormone, as well as DNA and conventional/pediatric vaccines. It also provides InsuJet system that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors.
NuGen Medical Devices Inc. Fundamentals Summary
| 79O fundamental statistics | |
|---|---|
| Market cap | €13.25m |
| Earnings (TTM) | -€5.16m |
| Revenue (TTM) | €234.45k |
62.8x
P/S Ratio-2.9x
P/E RatioIs 79O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 79O income statement (TTM) | |
|---|---|
| Revenue | CA$346.80k |
| Cost of Revenue | CA$176.35k |
| Gross Profit | CA$170.45k |
| Other Expenses | CA$7.80m |
| Earnings | -CA$7.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 49.15% |
| Net Profit Margin | -2,201.33% |
| Debt/Equity Ratio | -221.0% |
How did 79O perform over the long term?
See historical performance and comparison